Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immune Effects of Vedolizumab With or Without Etanercept in T1D
NCT05281614Phase 1Completed
- Sponsor
- Benaroya Research Institute
- Start
- Sep 2022
- Primary completion
- Jan 2024
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of vedolizumab in type 1 diabetes mellitus (T1D) (2 arms), sponsored by Benaroya Research Institute. Primary endpoints: 2-hour MMTT stimulated AUC C-peptide at 52 weeks, Adverse events of etanercept treatment at 52 weeks and 1 more. Started Sep 2022; status: completed.
02
Drugs
vedolizumab
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT05281614.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05281614.